Rx For Industry: Key Provisions Of The 21st Century Cures Act

Changes to the priority review voucher program, economic communications with payors, and approval of antimicrobial products all have the potential to impact the commercial prospects of drugmakers.

Capitol House

The roller-coaster ride of the 21st Century Cures Act is nearly complete, with the Senate voting 94-5 in favor on Dec. 7 in favor of the measure. It now moves on to President Obama, who said he will "sign it as soon as it reaches my desk."

While many of the pharmaceutical-related elements of the bill address a series of regulatory and R&D issues with the goal...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anti-infective

More from Therapeutic Category